• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 05, 2018 at 12:22: PM
via With an FDA approval for Fulphila, the first U.S. biosimilar to Amgen's Neulasta, Mylan will have its chance to launch a biosim to one of the biggest drug targets in the U.S. market.

article source
 

<



Similar threads

cafead
Amgen&#039;s Neulasta gains another biosimilar competitor as sales slip
Replies
0
Views
288
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Amgen&#039;s Neulasta banner draws OPDP’s second letter of 2021
Replies
0
Views
268
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sandoz resubmission puts Amgen&#039;s Neulasta at further risk of competition
Replies
0
Views
144
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Coherus prices biosimilar to Amgen&#039;s Neulasta at 33 percent discount
Replies
0
Views
313
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Amgen&#039;s marketing efforts help boost Tepezza sales
Replies
0
Views
68
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote